hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06304779 id: V3.0.2023.11.29 briefTitle: The Effect of Continuous Intravenous Infusion of Lidocaine on PPCs and Prognosis in Emergency Surgical Patients With IAI overallStatus: ACTIVE_NOT_RECRUITING date: 2023-10-31 date: 2025-09-30 date: 2026-06-30 date: 2024-03-12 date: 2024-03-12 name: Shanghai Zhongshan Hospital class: OTHER name: Tianjin Medical University General Hospital name: The Affiliated Hospital of Xuzhou Medical University name: West China Hospital briefSummary: The main purpose of this study is to evaluate the impact of continuous 24-hour intravenous infusion of lidocaine on the incidence of PPCs in patients undergoing emergency laparotomy for intra-abdominal infection (IAI).The secondary objectives of this study are to assess the impact of continuous 24-hour intravenous lidocaine infusion on the proportion of patients requiring mechanical ventilation, protection of important organ function during the perioperative period, length of hospital stay, and outcomes within 30 days postoperatively. conditions: Postoperative Pulmonary Complications conditions: Intra-abdominal Infection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Lidocaine group: Patients receive a loading dose of 1.5 mg/kg 2% lidocaine at anesthesia induction, followed by continuous intravenous infusion at 1.5 mg/kg/h until 24 hours postoperatively Control group: Patients receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively. primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 428 type: ESTIMATED name: Lidocaine name: Placebo measure: The impact of continuous 24-hour intravenous lidocaine on the incidence of PPCs in patients undergoing emergency laparotomy for IAI. measure: the impact of continuous 24-hour intravenous lidocaine infusion on the proportion of patients requiring mechanical ventilation, protection of important organ function during the perioperative period measure: To observe the impact of continuous perioperative lidocaine infusion on the levels of neutrophil extracellular traps (NETs) postoperatively sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhongshan Hospital,Fudan university city: Shanghai state: Shanghai zip: 200032 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06304766 id: H-23015954 briefTitle: Open Versus Laparoscopic Ablation of Liver Malignancies acronym: OPTIMAL overallStatus: RECRUITING date: 2023-12-15 date: 2025-12 date: 2025-12 date: 2024-03-12 date: 2024-03-13 name: Rigshospitalet, Denmark class: OTHER briefSummary: The purpose of this study is to compare laparoscopic ablation to open ablation of liver malignancies regarding complication rates and ablation response as well as quality of life following the surgery. conditions: Hepatocellular Carcinoma conditions: Cholangiocarcinoma conditions: Liver Metastases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Approximately 80 patients will be randomized 1:1 between laparoscopic or open ablation after operability assesment. primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Laparoscopic ablation name: Open ablation measure: Complications measured by the comprehensive complication index. measure: Tumor ablation completeness. measure: Quality of Recovery score (QoR) measure: Quality of Life score (QoL) measure: Overall survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rigshospitalet status: RECRUITING city: Copenhagen zip: 2100 country: Denmark name: Hans-Christian Pommergaard, MD DMSc PhD role: CONTACT email: hans-christian.pommergaard@regionh.dk lat: 55.67594 lon: 12.56553 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-05-01 uploadDate: 2023-10-06T05:58 filename: Prot_SAP_000.pdf size: 192543 hasResults: False
nctId: NCT06304753 id: BOT119435 briefTitle: ContriBution of Digital RemOte MoniToring to IMPROVing The Effectiveness of Treatment in Patients With Chronic Heart Failure With Low Ejection Fraction acronym: BOT-IMPROVE-HF overallStatus: RECRUITING date: 2023-10-27 date: 2025-07-01 date: 2025-12-01 date: 2024-03-12 date: 2024-03-12 name: I.M. Sechenov First Moscow State Medical University class: OTHER briefSummary: BOT-IMPROVE-HF is a two-center, parallel group study designed to evaluate the efficacy of up-titration of heart failure treatment using digital remote monitoring after hospitalization due to heart failure decompensation. Patient will be randomized before discharge using a simple computer generated sequence to either remote monitoring or usual care group. Patients' condition in the "remote monitoring" arm will be assessed by mini-program based on a personal messenger and laboratory rests results will be asked by phone call. If these measures show safety and tolerability of the doses of the drugs, they will be increased to target or maximally tolerated doses. The follow-up period will be 6 months - 24 weeks. Patients of the usual care group will be followed by their general practitioner and/or cardiologist. All patients will be contacted after 6 months to assess outcomes. conditions: Chronic Heart Failure With Low Ejection Fraction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Telebot measure: All-cause mortality measure: Heart failure decompensation measure: Change in NT-proBNP measure: Change in Quality of life measure: Changes in medical adherence sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Therapy No. 1 Department, University Clinical Hospital No. 1, Sechenov University status: RECRUITING city: Moscow zip: 119435 country: Russian Federation name: Maria Kozhevnikova role: CONTACT phone: +7 (499) 248-46-43 email: kozhevnikova_m_v@staff.sechenov.ru name: Aleksei Emelianov role: CONTACT phone: +7 (999) 830-57-85 email: emelyanov_a_v@staff.sechenov.ru lat: 55.75222 lon: 37.61556 facility: State Budgetary Institution of Healthcare of Moscow "A.K. Yeramishantsev City Clinical Hospital of the Department of Healthcare of Moscow". status: RECRUITING city: Moscow zip: 129327 country: Russian Federation name: Maria Kozhevnikova role: CONTACT phone: +74992484643 email: kozhevnikova_m_v@staff.sechenov.ru name: Aleksei Emelianov role: CONTACT phone: +79998305785 email: emelyanov_a_v@staff.sechenov.ru lat: 55.75222 lon: 37.61556 hasResults: False
nctId: NCT06304740 id: IMG-007-102 briefTitle: Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants overallStatus: RECRUITING date: 2024-03-06 date: 2024-09 date: 2024-09 date: 2024-03-12 date: 2024-03-22 name: Inmagene LLC class: INDUSTRY briefSummary: This is a double-blind, randomized, placebo-controlled study to assess the safety and PK profile of a single subcutaneous dose of IMG-007 in healthy participants. The study will comprise of a 5-week screening period, a 3-day In-patient Period in a clinical research unit (CRU) and an Out-patient Follow-up Period up to 127 days. The study will include 3 dose cohorts which will be enrolled sequentially. Participants will receive a single subcutaneous dose of IMG-007 or placebo at Baseline according to their assigned dose. conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: IMG-007 name: Placebo measure: Adverse Event Evaluation measure: Pharmacokinetic Parameters, Cmax measure: Pharmacokinetic Parameters, Tmax measure: Pharmacokinetic Parameters, AUC0-t sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Linear Clinical Research status: RECRUITING city: Perth country: Australia lat: -31.95224 lon: 115.8614 hasResults: False
nctId: NCT06304727 id: 23-5064 id: Easydore type: OTHER domain: 69HCL23_0736 briefTitle: Evaluation of Short Enteral Nutrition in the Emergency Room for Bronchiolitis With Main Nutritional Impairment acronym: 1TreSBCD overallStatus: RECRUITING date: 2022-11-21 date: 2024-06-01 date: 2024-06-30 date: 2024-03-12 date: 2024-03-12 name: Hospices Civils de Lyon class: OTHER briefSummary: The winter epidemic of bronchiolitis in infants poses insurmountable difficulties for the hospital system for the 2022-2023 season globally. These difficulties are linked to the combination of an unusual epidemic intensity and the loss of medical and paramedical caregivers in the hospital leading to the closure of beds since the Covid-19 pandemic. Bronchiolitis in youngest and most vulnerable infants can lead to severe clinical pictures requiring hospitalization. Among them, some infants present exclusively with inability to eat and only require continuous enteral nutrition during their hospitalization.
A retrospective evaluation of the feasibility and effectiveness of this protocol is necessary to rely on this first experience of outpatient management. conditions: Bronchiolitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 200 type: ESTIMATED name: clinical data review measure: Feasibility of the short enteral feeding protocol sex: ALL minimumAge: 8 Weeks maximumAge: 1 Year stdAges: CHILD facility: Hopital Femme Mere Enfant status: RECRUITING city: Bron country: France name: Dominique PLOIN, MD role: CONTACT phone: 0427855642 phoneExt: +33 email: dominique.ploin@chu-lyon.fr name: Côme HORVAT, MD role: CONTACT phone: 0427855634 phoneExt: +33 email: come.horvat@chu-lyon.fr lat: 45.73333 lon: 4.91667 hasResults: False
nctId: NCT06304714 id: 20_RIPH3-16 id: 2022-A00162-41 type: OTHER domain: ANSM (National Agency for the Safety of Medicines and other health products ) briefTitle: Effects of Bothrops Spp. Snake Envenomation on Willebrand Factor Activity in Martinique and French Guiana acronym: WBOTHROPS overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-10-08 date: 2025-10-08 date: 2024-03-12 date: 2024-03-12 name: University Hospital Center of Martinique class: OTHER name: University Hospital, Lille briefSummary: In 2017, the World Health Organization placed snakebites at the top of its list of neglected tropical diseases in an effort to facilitate funding for prevention programs, improve access to anti-venom, and stimulate new research in this area. Between 5 and 25 cases per 100 000 inhabitants are reported per year in French Guiana and Martinique. Before the era of anti-venom immunotherapy, envenomations by Bothrops snake bites in French Guiana and Martinique could quickly become life-threatening with a mortality rate close to 30%. Today, the administration of fragments of Fab or (Fab')2 immunoglobulins gives anti-venoms an excellent capacity to neutralise venom toxins, which has reduced mortality to less than 1% in the case of early hospital treatment In French Guiana, envenomation by Bothrops bites is characterized by local signs such as intense pain, rapidly expanding oedema, haemorrhagic phlyctenes and sometimes muscle necrosis. The local inflammatory and haemorrhagic damage is related to the enzymatic activities of the toxins contained in the venom (metallo-proteinases, disintegrins, and phospholipases A2, in particular). At the systemic level, venom serine proteases and metalloproteinases activate the coagulation cascade by multiple mechanisms (activation of coagulation factors X and V and of protrombin, thrombin-like and fibrinogenolytic enzymatic properties) and are responsible for the collapse of coagulation factors making the blood incoagulable. The metalloproteinases "hemorrhagins" destroy the vessel wall and are the cause of locoregional and systemic hemorrhage.
Envenomations by bites of Bothrops lanceolatus in Martinique have particular characteristics. Despite the genetic similarity with their congeners in French Guiana, envenomation by bites of Bothrops lanceolatus is characterized by the development of very intense local inflammatory signs (little haemorrhage) and the occurrence of thrombotic complications such as cerebral, pulmonary or myocardial infarction. The mechanisms behind this thrombotic presentation are not known. The large amount of metalloproteinases in the composition of Bothrops lanceolatus venom is believed to be responsible for destruction of vascular endothelium and pro-thrombotic state. Bothrops lanceolatus bite envenomations have been reported to be frequently complicated by generalized infections, disseminated intravascular coagulation and the occurrence of multi-visceral failure syndrome. This observation suggests abnormalities in endothelial function in which changes in Willebrand factor expression have been implicated.
The investigators hypothesize that plasma Willebrand factor (VW) activity and the intensity of endothelial activation are different depending on the Bothrops snake species involved in the bites in Guyana and Martinique. Due to the specific properties of the venoms of each Bothrops species, the activity of the Willebrand factor (VW) and the consequences in terms of endothelial activation would be different and responsible for the clinico-biological characteristics according to the geographical origin of the snakes.
This study will highlight the importance of changes in Willebrand factor activity on endothelial activation and the initiation of micro-thrombosis in the case of Bothrops lanceolatus envenomations and on primary haemostasis and bleeding disorders in the case of endemic Bothrops in Guyana. This new knowledge is important insofar as individualised therapeutic management can be proposed. Indeed, several studies have shown that adjuvant treatment of thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura, with blood products (fresh frozen plasma) or plasma exchange, improves endothelial dysfunction and the prognosis of patients. conditions: Snake Envenomation conditions: Thrombi conditions: Coagulopathy conditions: Hemorrhage studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Patients suffering from envenomation by Bothrops measure: Plasma Willebrand factor (VW:Act) activity prior to administration of the anti-venom (Bothrofav® or Antivipmyn-tri®). measure: Plasma VW factor activity (VW:Act/VW:Ag ratio) measure: Hemostasis abnormalities measure: Plasma levels of high-molecular-weight VW factor multimers assessed by electrophoresis technique measure: Plasma concentrations of soluble forms of the endothelial adhesion molecules sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06304701 id: PI-2023-08 briefTitle: Handwritten Text Production in Adults With Autism acronym: PEMTAA overallStatus: RECRUITING date: 2023-11-29 date: 2025-05 date: 2025-05 date: 2024-03-12 date: 2024-03-12 name: Centre Hospitalier de Niort class: OTHER name: University of Poitiers briefSummary: The main objective is to assess the psycholinguistic and graphomotor characteristics of written production in patients with ASD.
* Results obtained in tests (writing habits questionnaire, Autism Diagnostic Observation Scale (second edition), Wechsler Adult Intelligence Scale (fourth edition) - Similarities subtest, Wechsler Adult Intelligence Scale (fourth edition) - Vocabulary subtest, Rey Figure, MASC). conditions: Autism Spectrum Disorder studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study is part of category 2 of research involving humans and which corresponds to an interventional study with minimal risks and constraints. The patient is asked to return to carry out this study. primaryPurpose: DIAGNOSTIC masking: NONE count: 38 type: ESTIMATED name: Cognitive and writing tests measure: Assessment of psycholinguistic and graphomotor characteristics of written production in patients with autism spectrum disorder (asd) measure: Identifying links between specific deficits of ASD and difficulties in written production measure: Identifying links between the severity of ASD and difficulties in written production sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre Hospitalier de Niort status: RECRUITING city: Niort zip: 79000 country: France name: Diane D Chuillet-Moreau, Mrs role: CONTACT phone: +33549782049 email: diane.chuillet-moreau@ch-niort.fr lat: 46.32313 lon: -0.45877 hasResults: False
nctId: NCT06304675 id: 905055423985 briefTitle: Manageable Environmental Factors in Migraine overallStatus: COMPLETED date: 2023-09-30 date: 2024-02-15 date: 2024-03-04 date: 2024-03-12 date: 2024-03-12 name: Samsun University class: OTHER briefSummary: There is limited and insufficient information on the effects of inappropriate living environments, exposure to allergens, electromagnetic fields and stress factors on the chronicity of migraine. The aim of this study is to investigate the frequency of environmental variables/triggers in episodic and chronic migraine patients and their relationship with clinical variables in the chronic migraine group. The results obtained will be shared not only in the scientific community, but also on workplace health and employer-related platforms, including "Wellbeing" groups. conditions: Migraine studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ACTUAL name: no intervention measure: 1. Environmental factors/triggers affecting the chronicity of migraine measure: 2.Environmental factors/triggers and migraine treatment sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Samsun University city: Samsun zip: 55100 country: Turkey lat: 41.27976 lon: 36.3361 hasResults: False
nctId: NCT06304662 id: *University of Jaén briefTitle: Yoga for Physical and Mental Health overallStatus: COMPLETED date: 2023-11-13 date: 2024-02-09 date: 2024-02-19 date: 2024-03-12 date: 2024-03-26 name: University of Jaén class: OTHER briefSummary: In the university environment, where academic pressure and personal exploration are paramount, yoga serves as a sanctuary for students facing stress and seeking self-discovery. Through practices like asanas, pranayama, and meditation, yoga equips students with tools to manage stress, foster inner balance, and enhance emotional well-being. Apart from its emotional benefits, yoga offers physical advantages, improving strength, flexibility, and posture, particularly beneficial for those sedentary due to academic demands. Moreover, yoga enhances concentration and mental clarity through mindfulness practices, aiding students in academic focus and problem-solving.Additionally, yoga provides a space for students to disconnect from external stimuli and recharge, reducing mental and physical fatigue while boosting vitality. By integrating yoga into university life, students can better balance academic pressures with personal care, laying the groundwork for a more harmonious and mindful future. conditions: Stress studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 142 type: ACTUAL name: Yoga intervention measure: D2 test measure: Mindful Attention Awareness Scale (MAAS) measure: Handgrip Strength measure: Anxiety and Depression measure: Sleep quality measure: Stress level measure: The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) measure: State Anxiety Inventory (STAI) measure: Attentional Control: Shifting and Distraction (AC-S and AC-D) measure: Positive and Negative Affect Schedule measure: Difficulties in Emotion Regulation Scale (DERS) sex: ALL minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: Agustín Aibar Almazán city: Jaén zip: 23007 country: Spain lat: 37.76922 lon: -3.79028 hasResults: False
nctId: NCT06304649 id: Cast21CHLA2023Study1SAP briefTitle: Clinical Evaluation of Cast21 Short Arm Product During Treatment of Distal Radial or Distal Ulnar Fractures acronym: Cast21 SAP overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-10 date: 2024-12 date: 2024-03-12 date: 2024-03-12 name: Cast21 class: INDUSTRY briefSummary: The primary objective of this study will be the collection of preliminary clinical evidence to indicate that Cast21 Short Arm Product is no worse than the current standard of care arm immobilization devices in pediatric patients.
A secondary objective will be to characterize the clinician and patient experience with the Cast21 Short Arm Product. conditions: Fractures, Closed conditions: Fractures Bone conditions: Fracture conditions: Fractures conditions: Radius; Fracture, Lower or Distal End conditions: Ulna Fractures conditions: Radius Distal Fracture studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Cast or brace alternative measure: Clinical determination of healing (standard of care) measure: Range of Motion (standard of care) measure: Patient Reported Outcomes - Pain measure: Patient Reported Outcomes - Satisfaction measure: Physical Therapy Referral sex: ALL minimumAge: 3 Years maximumAge: 21 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06304636 id: DC15-MM-01 briefTitle: Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma acronym: DC15-MM-01 overallStatus: RECRUITING date: 2024-03-01 date: 2026-12-01 date: 2027-10-01 date: 2024-03-12 date: 2024-03-12 name: Cartesian Therapeutics class: INDUSTRY briefSummary: This is a Phase I dose-escalation study to evaluate the safety, tolerability and preliminary efficacy of an autologous BCMA-targeting RNA-engineered CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma. The cell product is referred to as Descartes-15 conditions: Refractory Multiple Myeloma conditions: Relapsed Multiple Myeloma studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Study consists of two parts. Part 1 is a single-arm dose escalation study. Part 2 is a dose-expansion study with 2 arms. primaryPurpose: TREATMENT masking: NONE count: 41 type: ESTIMATED name: Descartes-15 measure: Determine the safety of Descartes-15 in patients with relapsed/refractory multiple myeloma (R/R MM) measure: To assess the anti-myeloma activity of Descartes-15, as measured by IMWG response criteria and progression-free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Center for Cancer and Blood Disorders (AON) status: RECRUITING city: Bethesda state: Maryland zip: 20817 country: United States lat: 38.98067 lon: -77.10026 hasResults: False
nctId: NCT06304623 id: CIRE.112 briefTitle: SVF for Treating Pulmonary Fibrosis Post COVID-19 acronym: SVFCOVID-19 overallStatus: COMPLETED date: 2020-05-05 date: 2024-03-01 date: 2024-03-01 date: 2024-03-12 date: 2024-03-12 name: Michael H Carstens class: OTHER name: Ministerio de Salud de Nicaragua name: Wake Forest University name: National Autonomous University of Nicaragua briefSummary: General description of the study